Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 3/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.60 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.44 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.44 |
| ▸ | PNP | P00491 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12104062 | 0.82 | LMNA (0.58) | DNMT1LMNATP53HTTSMN1; SMN2 | |
| SCHEMBL13984568 | 0.82 | DNMT1 (0.50) | DNMT1ADRB1PNPLMNATP53 | |
| SCHEMBL14089414 | 0.82 | DNMT1 (0.52) | DNMT1ADRB1PIM1CSNK2A2CSNK2B | |
| SCHEMBL12746575 | 0.80 | DNMT1 (0.64) | DNMT1ADRB1PIM1CSNK2A2CSNK2B | |
| SCHEMBL3280007 | 0.80 | DNMT1 (0.59) | DNMT1ADRB1PIM1CSNK2A2CSNK2B | |
| SCHEMBL3280010 | 0.80 | DNMT1 (0.59) | DNMT1ADRB1PIM1CSNK2A2CSNK2B | |
| SCHEMBL17359215 | 0.79 | ADRB1 (0.69) | DNMT1ADRB1PIM1CSNK2A2CSNK2B | |
| SCHEMBL14089658 | 0.79 | ADRB1 (0.47) | DNMT1ADRB1LMNA | |
| SCHEMBL14089974 | 0.79 | DNMT1 (0.57) | DNMT1ADRB1PIM1CSNK2A2CSNK2B | |
| SCHEMBL7915397 | 0.78 | DNMT1 (0.58) | DNMT1ADRB1LMNATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46144-E1 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9096627-B2 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140066419-A1 | HYDROXAMIC ACID DERIVATIVES | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20110269706-A1 | Hydroxamic Acid Derivatives | NORTHLAKE BIOSCIENCES LLC (US) | 2011-11-03 | — | — | US | disclosed |
| WO-2010085377-A2 | HYDROXAMIC ACID DERIVATIVES | CRYSTAL BIOPHARMACEUTICAL LLC (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066419-A1 | HYDROXAMIC ACID DERIVATIVES | HDAC5, HDAC7, HDAC4 | DNMT1 1391/4885ADRB1 4787/4885PIM1 3760/4885 |
| US-20110269706-A1 | Hydroxamic Acid Derivatives | CD74, HLA-DRB1, HDAC5 | DNMT1 855/4885ADRB1 4882/4885PIM1 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.